IP Library › Granted Patent US 11,008,384
Granted Patent B2
US 11,008,384 · App. 16/707,157 · Granted May 18, 2021

Anti-tenascin C antibodies and uses thereof

Inventors: Kim Suzanne Midwood (Buckinghamshire, GB); Philip Antony Bland-Ward (London, GB); Nigel Burns (London, GB); Patrick John Hextall (Cambridge, GB); Susan Rebecca Aungier (Oxford, GB)
Assignee: STERLING IP LIMITED
C07K16/18A61K39/3955C07K14/78G01N33/6893A61K2039/505C07K2317/33C07K2317/55C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,008,384
App. No.
16/707,157
Granted
May 18, 2021
Kind
B2
Abstract

There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.

Claims (26)

1. An isolated nucleic acid molecule encoding an anti-fibrinogen-like globe (FBG) domain of a tenascin-C antibody or binding fragment, comprising a VH region wherein CDRH1 is SEQ ID NO: 9, CDRH2 is SEQ ID NO: 10, CDRH3 is independently selected from SEQ ID NO: 11, 30, 32, 34, 36, 38, 40, 42, 44, and 46, and a VL region wherein a CDRL1 is SEQ ID NO: 5, CDRL2 is SEQ ID NO: 13 and CDRL3 is SEQ ID NO: 14.

2. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 11.

3. An isolated nucleic acid molecule according to claim 2 , wherein the VH region comprises SEQ ID NO: 12.

4. An isolated nucleic acid molecule according to claim 1 , wherein CDRH3 is SEQ ID NO: 30.

5. An isolated nucleic acid molecule according to claim 4 , wherein the VH region comprises SEQ ID NO: 31.

6. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 32.

7. An isolated nucleic acid molecule according to claim 6 , wherein the VH region comprises SEQ ID NO: 33.

8. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 34.

9. An isolated nucleic acid molecule according to claim 8 , wherein the VH region comprises SEQ ID NO: 35.

10. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 36.

11. An isolated nucleic acid molecule according to claim 10 , wherein the VH region comprises SEQ ID NO: 37.

12. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 38.

13. An isolated nucleic acid molecule according to claim 12 , wherein the VH region comprises SEQ ID NO: 39.

14. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 40.

15. An isolated nucleic acid molecule according to claim 14 , wherein the VH region comprises SEQ ID NO: 41.

16. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 42.

17. An isolated nucleic acid molecule according to claim 16 , wherein the VH region comprises SEQ ID NO: 43.

18. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 44.

19. An isolated nucleic acid molecule according to claim 18 , wherein the VH region comprises SEQ ID NO: 45.

20. An isolated nucleic acid molecule according to claim 1 , wherein the CDRH3 is SEQ ID NO: 46.

21. An isolated nucleic acid molecule according to claim 20 , wherein the VH region comprises SEQ ID NO: 47.

22. An isolated nucleic acid molecule according to claim 1 , wherein the VL region comprises SEQ ID NO: 15.

23. An isolated nucleic acid molecule according to claim 1 , wherein the VL region comprises SEQ ID NO: 125.

24. A vector comprising the nucleic acid molecule of claim 1 .

25. A host cell comprising the nucleic acid molecule of claim 1 .

26. A host cell comprising the vector of claim 24 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2021
From: NASCIENT LIMITED
To: STERLING IP LIMITED
Reel/Frame 055800/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2020
From: MIDWOOD, KIM SUZANNE; BLAND-WARD, PHILIP ANTONY; BURNS, NIGEL; HEXTALL, PATRICK JOHN; AUNGIER, SUSAN REBECCA
To: NASCIENT LIMITED
Reel/Frame 052506/0412 →
Priority Claims (1)
GB 1414021 · Aug 7, 2014 · national
Continuity (3)
Continuation 16104610 · Aug 17, 2018
Continuation 15501979
Related Publication 20200190177A1 · Jun 18, 2020